Why Visa and Mastercard Shares Fell By Nearly 5%
Considered a core holding that would never fall, Visa (V) and Mastercard (MA) did just that. A report that two retail giants – Amazon (AMZN) and Walmart (WMT) – would bypass the credit card firms sent MA and V stock down by 4.62% and 4.99%, respectively.The two retailers might consider a stablecoin payment system that bypasses credit cards. This would save Walmart and Amazon from paying their significantly high fees. Shift4 Payments (FOUR), Block (XYZ), Paysafe (PSFE), and PayPal Holdings (PYPL) shares also fell on June 13.Unjustified FearsRetailers may add unnecessary risks by using stablecoins. They may open themselves up to hacking and cybersecurity risks. Conversely, Visa and Mastercard have an established network, strong security, and a dedicated customer support team. Stablecoin may not have the maturity to handle everyday grocery shopping at Walmart.Customers would not benefit from a stablecoins-based system. Retailers would not pass the savings to their customers. As retailers boost profits, customers may avoid the new transaction options, citing safety concerns.The UST collapse in May 2022 offers lessons about the use of algorithmic stablecoins. Companies would need to study the timeline. The pros and cons of using them over credit cards might cause the firms to consider dismissing stablecoin use.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


